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Arthritis in Kawasaki disease: A poorly recognised manifestation
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Aim: To determine the prevalence of arthritis in Kawasaki disease (KD) and the clinical characteristics of children with KD and arthritis.
Methods: This was a single-centre, 15-year, retrospective study of children admitted with KD. Clinical features (including coronary involvement),
laboratory results and treatment response were evaluated.
Results: Of 63 children with KD, 60.3% were male, with a median of age of 2.0 years. Complete KD was found in 68.3%. The time from symptom
onset to treatment was 7.0 days (median); 30.7% had coronary artery aneurysms, from which 82.5% responded to intravenous immunoglobulin.
During the course of their illness, eight children developed arthritis (12.7%), which was early onset in six (75%) and oligoarticular in five (62.5%).
The median number of joints was 3.5 (P25 = 1.3, P75 = 17.0), and at least one large joint was affected. In all cases, the arthritis was self-limited
and left no sequelae, lasting a median of 14 days and no longer than 22 days. KD children with arthritis were older (P = 0.025), and those with
early-onset arthritis responded to first-line therapy, unlike the late-onset group (P = 0.018).
Conclusions: This study emphasises the value of a systematic articular examination of joints in KD. Refractory KD was observed in children with
late-onset arthritis.
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What is already known on this topic
1 Arthritis has long been described in Kawasaki disease (KD) but
has had a dramatic decrease since the intravenous immunoglob-
ulin (IVIG) era.
2 Literature has shown that this subgroup of patients appears to
have a more pronounced systemic inflammation and IVIG resis-
tance (refractory KD).
What this paper adds
1 The prevalence of arthritis found in our cohort (12.7%) was
higher than reported by others (2–7.5%) in the post-IVIG era.
2 The presence of early-onset arthritis is associated with a good
response to first-line therapy.
3 Late-onset arthritis might be associated with refractory KD.
Kawasaki disease (KD) is an acute, self-limited, inflammatory,
medium-vessel vasculitis of unknown aetiology that mainly
affects young children.1,2 It is the most common cause of acquired
heart disease in children in developed countries.1 KD is charac-
terised by fever, bilateral non-exudative conjunctivitis, erythema
of the lips and oral mucosa, changes in the extremities, polymor-
phous rash and cervical lymphadenopathy.3 Coronary artery
lesions appear in 15–25% of untreated children.1
KD may present with non-cardiac manifestations in almost every
organ and system.1 Arthritis in KD has long been described and was
reported in 31% of patients in the pre-intravenous immunoglobu-
lin (IVIG) era.2 The prevalence decreased to 2–7.5% due to the
anti-inflammatory effect of IVIG.2,4 Although joint involvement has
not been specifically associated with a worst outcome, a body of lit-
erature has demonstrated that this subgroup of patients has a more
pronounced systemic inflammation and IVIG resistance.2,5 Arthritis
in KD is mainly described in case reports.2,6,7 It is not a major diag-
nostic criterion in KD. It is possible that the presence of arthritis in
KD is missed as joints cannot be easily assessed in a febrile irritable
child.4
The purpose of this study is to determine the prevalence of
arthritis associated with KD, its clinical pattern, treatment response
and prognosis in relation to the coronary outcome.
Methods
Subjects and data
We did a retrospective single-centre study of children admitted to
a Portuguese paediatric tertiary hospital with a diagnosis of KD
during a 15-year period from January 1998 to December 2013.
The diagnosis, treatment and management of KD were estab-
lished according to the American Heart Association (AHA) Guide-
lines.1,8 Treatment included IVIG (2 g/kg) and high-dose aspirin
(80–100 mg/kg/day) until the child is afebrile for 48–72 h, reduc-
ing to low dose (3–5 mg/kg) until there is no evidence of coro-
nary artery lesions by 6–8 weeks. Non-responders to the first-line
therapy received a second course of 2 g/kg IVIG and, if still
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unresponsive, were subsequently treated with steroids. Cardiac
involvement was defined according to AHA 1994 and 2004
guidelines.1,8
A paediatric consultant in rheumatology examined all children
with arthritis, defined as joint pain with limited range of motion
and/or swelling and/or evidence of synovitis on ultrasonography.
Oligoarticular involvement was considered if less than five active
joints were present and polyarticular involvement for five or more
active joints.9 Early- and late-onset arthritis were, respectively, estab-
lished according to its onset, until or after the 10th day of illness.1
Statistical analysis
An exploratory analysis was carried out for all variables. Non-
parametric χ2, Fisher’s exact and Mann–Whitney tests were used,
with a level of significance of α = 0.05. All data were analysed
using SPSS, version 22.0 (IBM Corp., Armonk, NY, USA).
Results
Sixty-three children were diagnosed with KD; 38 (60.3%) were
male, and 41 (83.7%) were Caucasian. The median age at diagno-
sis was 2.0 years (range 2.4 months–11.5 years). Complete KD
was observed in 43 patients (68.3%). The median time from
symptom onset to definitive treatment was 7.0 days (P25 = 5.0,
P75 = 9.0). Most patients responded to the first IVIG dose (82.5%),
11 needed additional IVIG, 5 required steroids and 1 infliximab.
The incidence of coronary artery aneurysms was 30.1%.
Eight children developed arthritis during the course of their ill-
ness (12.7%). Table 1 further describes the clinical features.
The median time lapse from symptom onset to the appearance
of arthritis was 4.5 days (min = 2.0; max = 14.0). Early-onset
and late-onset arthritis were, respectively, observed in six
(75.0%) and three (37.5%) patients (one patient had both pre-
sentations). The number of joints affected ranged from 1 to
35, and at least one large joint was affected. Five (62.5%) had
oligoarticular involvement and three (37.5%) polyarticular, in
which small joints of the hand were always symmetrically
involved.
The median duration of articular involvement was 14 days
(P25 = 8.0, P75 = 18.0), lasting no longer than 22 days. An addi-
tional non-steroidal anti-inflammatory drug (ibuprofen) was
needed in patients with polyarticular presentation; however, only
one (patient 8) required non-steroidal anti-inflammatory drugs
after discharge. All patients with arthritis recovered, with no joint
sequelae.
Regarding KD children with and without arthritis, those with
articular involvement were older and had higher haemoglobin
levels (Table 2). Three of the 8 children with arthritis (37.5%) and
16 of the 55 children without arthritis had coronary artery involve-
ment (29.1%). The difference was not statistically significant.
Five of six patients with early-onset arthritis responded to the
first IVIG course, unlike all patients with late-onset arthritis
(patients 4, 6 and 8), who required a second IVIG course or even
methylprednisolone (P = 0.018). Patient 4 had a complete KD
and responded to a first IVIG course at day 8. However, on day
14, the fever relapsed, accompanied by oligoarthritis, and only
remitted after a second IVIG course. Patient 6 had a mixed
arthritic pattern, with acute left knee arthritis on day 4, which
resolved a few days after a second IVIG dose. Nevertheless, fever
persisted, and arthritis relapsed on day 11, involving 35 joints.
Another patient (patient 8) did not respond after two IVIG
courses and, on day 11, presented with polyarthritis to a total
joint count of 14. Both patients 6 and 8 needed a methylprednis-
olone course for complete recovery.
Discussion
KD is a multisystem vasculitis, affecting mostly medium-sized
arteries. The articular involvement in KD has been reported,


















1 M 10 C 14 One dose IVIG 2 1 Early One ankle 0 8
2 F 2 C 6 One dose IVIG 5 2 Early One hip 1 MCP 2
3 F 2 C 6 One dose IVIG 4 4 Early Two shoulders,
two knees
0 ND
4 F 3 C 7 Two doses IVIG 14 3 Late Two hips, one knee 0 11
5 M 3 I 14 One dose IVIG 3 1 Early One hip 0 22
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8 M 3 C 4 Two doses IVIG,
one dose MP
11 14 Late Two elbows, two knees 10 PIP 18
C, complete; DIP, distal interphalangeal joint; F, female; I, incomplete; IVIG, intravenous immunoglobulin; M, male; MCP, metacarpophalangeal joint; MP,
methylprednisolone; ND, not determined; PIP, proximal interphalangeal joint.
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although poorly characterised.1 The prevalence of arthritis in KD
arthritis has decreased dramatically since the introduction of IVIG
therapy, making it even more difficult to describe.2,4 Interest-
ingly, the prevalence of arthritis found in our cohort (12.7%),
although higher than reported by others (2–7.5%), was signifi-
cantly lower in comparison to the prevalence in pre-IVIG
era (31%).2
Arthritis in KD is generally self-limited, and intensely painful,
conditioning a limping gait.2 Affected children are reported to
have the same demographic features of children without arthritis;
however, our data showed that arthritis in KD mainly affected
older children.
In the pre-IVIG era, early-onset polyarthritis was more com-
mon; it developed during the first 10 days of illness and tended
to involve multiple joints, including small and large weight-
bearing joints.9 This type of arthritis is often undistinguishable
from systemic juvenile idiopathic arthritis.7,10 Late-onset arthritis
(sub-acute stage) occurs after the 10th day of illness and is
mainly oligoarticular, involving large weight-bearing joints.1,2 In
our study, early-onset arthritis was the most frequent presenta-
tion; an oligoarticular pattern was dominant. In a remarkable
fashion, one patient presented with a biphasic pattern, early-
onset arthritis was followed by late-onset arthritis, as already
been reported by Duzova et al.11
It has been suggested that arthritis in KD might lead to a worse
outcome7,10 because it indicates a more intense inflammatory
response,2 accounting for some of the first-line therapy resistance.5
However, Gong et al. did not find any association between the artic-
ular involvement and worse prognosis or higher inflammatory
response.2 Curiously, we found higher haemoglobin levels at admis-
sion in patients with arthritis, a finding also noted by Gong et al.2
We acknowledge that this may be due to the fact that haemoglobin
level is influenced by age, with higher levels in older children.
Early-onset arthritis in KD has been reported to correlate with
a worse outcome.11 However, in our cohort, five of six patients
with early-onset arthritis responded to the first course of IVIG.
Instead, late-onset arthritis was associated with refractory
KD. Our study suggests that first-line therapy with IVIG is indi-
cated irrespective of articular involvement in KD and that the
presence of late-onset arthritis in refractory KD should be taken
into consideration when choosing the second line of treatment.
Further studies are required to ascertain the role of arthritis in
refractory KD in the determination of the most appropriate
second line of treatment. In our study, arthritis in KD was not
associated with the increased risk of coronary artery involvement.
Our study has several limitations. It is a retrospective analysis
of a small-sized sample, and the diagnostic criteria for coronary
artery abnormalities according to AHA guidelines changed over
the study period. Finally, we cannot rule out if arthritis was
underestimated in younger children as it is difficult to diagnose
arthritis in this age group, especially in the presence of swelling
and induration of hands and feet.
Conclusions
This study shows the importance of a systematic evaluation of
articular involvement in KD. We suggest that, in general, early-
onset arthritis is associated with a good response to the first-line
therapy in KD and that late-onset arthritis might indicate
refractory KD.
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